Drug Profile
R-bambuterol - Lotus Pharmaceuticals
Alternative Names: Laevo bambuterolLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dong Guan Kai Fa Biologicals Medicine
- Developer Lotus Pharmaceuticals
- Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (PO, Tablet)
- 27 Oct 2010 State Food and Drug Administration approves phase I pharmacokinetic trial of R-bambuterol in healthy volunteers in China
- 26 Aug 2010 Phase-I clinical trials in Asthma (in volunteers) in China (PO)